Mouse monoclonal primary
IMP-3 Mouse Monoclonal Antibody [C2-E4] (EM1701-15)
Hela, 293T, SH-SY5Y, rat brain tissue, human liver cancer tissue, human placenta tissue, mouse testis tissue, HUVEC.
Store at +4C after thawing. Aliquot store at -20C or -80C. Avoid repeated freeze / thaw cycles.
1*PBS (pH7.4), 0.2% BSA, 50% Glycerol. Preservative: 0.05% Sodium Azide.
Protein A purified.
Cancer/testis antigen 98 antibody; CT98 antibody; DKFZp686F1078 antibody; hKOC antibody; IF2B3_HUMAN antibody; IGF II mRNA binding protein 3 antibody; IGF-II mRNA-binding protein 3 antibody; IGF2 mRNA binding protein 3 antibody; IGF2 mRNA-binding protein 3 antibody; IGF2BP3 antibody; IMP 3 antibody; IMP-3 antibody; Insulin like growth factor 2 mRNA binding protein 3 antibody; Insulin-like growth factor 2 mRNA-binding protein 3 antibody; KH domain containing protein overexpressed in cancer antibody; KH domain-containing protein overexpressed in cancer antibody; KOC 1 antibody; KOC1 antibody; VICKZ 3 antibody; VICKZ family member 3 antibody; VICKZ3 antibody
Belongs to the RRM IMP/VICKZ family.
Expressed in fetal liver, fetal lung, fetal kidney, fetal thymus, fetal placenta, fetal follicles of ovary and gonocytes of testis, growing oocytes, spermatogonia and semen (at protein level). Expressed in cervix adenocarcinoma, in testicular, pancreatic and renal-cell carcinomas (at protein level). Expressed ubiquitously during fetal development at 8 and 14 weeks of gestation. Expressed in ovary, testis, brain, placenta, pancreatic cancer tissues and pancreatic cancer cell lines.
Insulin like growth factor 2 mRNA binding proteins (IGF2BPs) bind RNA and influence RNA synthesis and metabolism. IGF2BP1, also known as coding region determinant-binding protein/insulin-like growth factor II mRNA-binding protein (CRD-BP), IMP1 or VICKZ1; IGF2BP2 (IMP2, VICKZ2, p62); and IGF2BP2 (IMP3, KOC1, VICKZ3) contain a unique combination of RNA recognition motifs and four hnRNP K homology domains. IGF2BP1 is abundant in embryonal tissues and is expressed in 81% of colon cancers, 73% of sarcomas and 58.5% of breast cancers. It recognizes c-Myc, IGF-II and t mRNAs, and H19 RNA, and plays a major role in proliferation of K-562 cells by an IGF-II-dependent mechanism. IGF2BP2 binds the 5' UTR of IGF-II mRNA and influences tumor cell growth, in which IGF2BP2 is associated with apoptosis induced by tretinoin. IGF2BP3 knockdown by RNA interference decreases levels of IGF-II protein without affecting IGF-II, c-Myc, or β Actin mRNA and H19 RNA levels. IGF2BP3 is a marker for carcinomas and high-grade dysplastic lesions of pancreatic ductal epithelium.